Playing defense, Roche loses megafranchise gambit as Gazyva flunks head-to-head with Rituxan
A few weeks ago, Roche CEO Severin Schwan told reporters at Reuters that he was sleeping much better at night. The pharma giant reported some major progress on three key R&D fronts, including the recent news that Genentech’s blood cancer drug Gazyva had proved significantly better than its aging mainstay Rituxan in treating follicular lymphoma, after an earlier study highlighted a major improvement for progression-free survival in CLL.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
